DNA X Terminates $500M Equity Purchase Agreement with Chardan Capital
SONM sits 91% above its 52-week low of $2.521.
Summary
DNA X, Inc. ended its $500 million equity purchase agreement with Chardan Capital, removing a major potential financing option for the financially distressed company.
Key Events · Financing and Capital Events · SONM
-
Termination of ChEF Agreement
DNA X, Inc. and Chardan Capital Markets LLC mutually agreed to terminate the ChEF Purchase Agreement, which allowed for the sale of up to $500 million in common stock, effective May 28, 2026.
-
Removal of Major Financing Option
The termination removes a significant potential source of capital for the company, which had been in place since September 2025.
-
Context of Financial Distress
This event occurs as DNA X, Inc. faces a Nasdaq delisting notice and has previously disclosed a going concern warning, making the loss of a large potential financing facility particularly impactful.
Analysis · SONM · Manufacturing
DNA X, Inc. has terminated a significant equity purchase agreement that allowed it to sell up to $500 million in common stock to Chardan Capital Markets. This agreement, established in September 2025, represented a substantial potential financing source for the micro-cap company. Its termination removes a major capital-raising option, which is critical for a company that recently received a Nasdaq delisting notice and has a going concern warning. While the company has secured smaller financing rounds recently, the loss of this large facility could impact its long-term capital strategy.
At the time of this filing, SONM was trading at $4.81 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $2.52 to $38.52. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.